Enzymatica AB: Enzymatica signs distribution agreement with Endeavour Consumer Health
November 02 2016 - 10:00AM
Enzymatica has partnered with
Endeavour Consumer Health, a division of Symbion which is a member
of EBOS Group. The agreement grants Endeavour Consumer Health
exclusive rights to sell, market and distribute ColdZyme® in
Australia and New Zealand. It is Enzymatica's first agreement
outside the European Union (EU) and a breakthrough in the company's
strategic initiative to further establish ColdZyme in the
international market.
The agreement covers the products ColdZyme 20ml
and ColdZyme OneCold 7ml.
The regulatory requirements for medical devices in
Australia differ from those in the EU, meaning ColdZyme will be
registered in a higher class of medical devices. The registration
process is expected to take 12-18 months and the launch is planned
for 2018, ready for the cold & flu season in Australia.
"The agreement with Endeavour Consumer Health is
an important breakthrough in our strategic international expansion
outside Europe, and Endeavour Consumer Health is the perfect
partner for us. They are well established and have significant
experience launching new products to the market, which will favour
the introduction of ColdZyme in Australia and New Zealand", said
Fredrik Lindberg, CEO of Enzymatica.
EBOS Group's General Manager - Retail Services, Andrew Vidler, said
ColdZyme would complement Endeavour Consumer Health's existing
product offering.
"We are very excited about the agreement with
Enzymatica to sell ColdZyme in Australia. ColdZyme is different to
traditional cold therapies and fits well into our business model to
grow our business in the over the counter (OTC) health products
market with innovative new products."
For more information, please
contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
This information is information
that Enzymatica AB (publ) is obliged to make public pursuant to the
EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out
above, at 16.00 CET on November 2, 2016.
About Enzymatica
Enzymatica AB is a Life sciences company that develops and sells
medical devices for fighting infectious diseases. In a short period
of time, the company developed ColdZyme®, a unique mouth spray for
fighting colds, launched the product in seven markets and
established it as one of the bestselling cold products in Swedish
pharmacies measured in SEK. Our strategy is to continue growing by
strengthening our position on existing markets and expanding to
more geographic markets via established partners. The company's
head office is in Lund and it is listed on the Nasdaq First North.
For more information, please go to: www.enzymatica.se.
Enzymaticas Certified Adviser is Erik Penser
Bankaktiebolag.
About Endeavour Consumer
Health
Endeavour Consumer Health is a trans-Tasman business dedicated to
providing its retail partners and their customers with affordable,
high-quality health and personal care products.
The business was formed in 2014 from the
amalgamation of Symbion Consumer Products in Australia and the
consumer division of EBOS Healthcare in New Zealand and
Australia.
Endeavour Consumer Health is part of Symbion, a
member of EBOS Group Ltd. EBOS Group is the largest and most
diversified Australasian marketer, wholesaler and distributor of
healthcare, medical and pharmaceutical products.
For more information visit www.ebosgroup.com
Enzymatica Press Release Australia
161102 Final version
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024